List of Suppliers of Tirzepatide intermediates listed on PharmaCompass.com

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 2023788 19 2, Oyn3cci6qe, Ly3298176
Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist (RA), showed significantly greater glucose control and weight loss compared to the selective GLP-1 RA dulaglutide (DU) in a 26-week, randomized, double-blind Phase 2b study of type 2 diabetes patients.

USDMF

read-more
read-more

01

Formnext Forum
Not Confirmed

01

02

Formnext Forum
Not Confirmed

02

Formnext Forum
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39655

Submission : 2024-03-17

Status : Active

Type : II

blank

03

Shanghai Jingmai Pharmaceutical Scie...

Country

USDMF

arrow
Formnext Forum
Not Confirmed

03

Shanghai Jingmai Pharmaceutical Scie...

Country
arrow
Formnext Forum
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 40166

Submission : 2024-06-27

Status : Active

Type : II

blank

04

Hangzhou Thinheal Pharma-tech Co Ltd

Country

USDMF

arrow
Formnext Forum
Not Confirmed

04

Hangzhou Thinheal Pharma-tech Co Ltd

Country
arrow
Formnext Forum
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39900

Submission : 2024-06-28

Status : Active

Type : II

blank

05

Harbin Jixianglong Biotech Co Ltd

Country

USDMF

arrow
Formnext Forum
Not Confirmed

05

Harbin Jixianglong Biotech Co Ltd

Country
arrow
Formnext Forum
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39611

Submission : 2024-02-28

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-more

01

CordenPharma

Germany
ASC 2024
Not Confirmed
arrow

CordenPharma

Germany
arrow
ASC 2024
Not Confirmed

Terzepatide

Registrant Name : Korea Lily (U.S.)

Registration Date : 2023-06-28

Registration Number : Su253-11-ND

Manufacturer Name : Corden Pharma Colorado, Inc.

Manufacturer Address : 2075 55th Street, Boulder, Colorado (CO) 80301, United States (USA)

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

ASC 2024
Not Confirmed
arrow
arrow
ASC 2024
Not Confirmed

TIRZEPATIDE

NDC Package Code : 42973-383

Start Marketing Date : 2024-06-11

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

ASC 2024
Not Confirmed
arrow
arrow
ASC 2024
Not Confirmed

TIRZEPATIDE

NDC Package Code : 14403-0017

Start Marketing Date : 2024-04-26

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

03

ASC 2024
Not Confirmed
arrow
arrow
ASC 2024
Not Confirmed

TIRZEPATIDE

NDC Package Code : 76177-192

Start Marketing Date : 2023-01-10

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

04

NANJING XISHENGNUO BIOLOGICAL TECHN...

Country
ASC 2024
Not Confirmed
arrow

NANJING XISHENGNUO BIOLOGICAL TECHN...

Country
arrow
ASC 2024
Not Confirmed

TIRZEPATIDE

NDC Package Code : 83726-101

Start Marketing Date : 2023-01-01

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

05

Shenzhen Alvantis Pharma Co., Ltd.

Country
ASC 2024
Not Confirmed
arrow

Shenzhen Alvantis Pharma Co., Ltd.

Country
arrow
ASC 2024
Not Confirmed

TIRZEPATIDE

NDC Package Code : 84347-002

Start Marketing Date : 2024-05-23

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank

06

Xiamen TNV Biochem Tech. Co., Ltd

Country
ASC 2024
Not Confirmed
arrow

Xiamen TNV Biochem Tech. Co., Ltd

Country
arrow
ASC 2024
Not Confirmed

TIRZEPATIDE

NDC Package Code : 84666-001

Start Marketing Date : 2024-08-22

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

07

Hybio Pharmaceutical Co., Ltd. (Pin...

Country
ASC 2024
Not Confirmed
arrow

Hybio Pharmaceutical Co., Ltd. (Pin...

Country
arrow
ASC 2024
Not Confirmed

TIRZEPATIDE

NDC Package Code : 14403-0017

Start Marketing Date : 2024-06-26

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

08

Hybio Pharmaceutical Co., Ltd. (Pin...

Country
ASC 2024
Not Confirmed
arrow

Hybio Pharmaceutical Co., Ltd. (Pin...

Country
arrow
ASC 2024
Not Confirmed

TIRZEPATIDE

NDC Package Code : 14403-0017

Start Marketing Date : 2024-06-26

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

09

MAEDA INC

Country
ASC 2024
Not Confirmed
arrow

MAEDA INC

Country
arrow
ASC 2024
Not Confirmed

TIRZEPATIDE

NDC Package Code : 86184-392

Start Marketing Date : 2024-03-01

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

10

NUCARE API LLC

Country
ASC 2024
Not Confirmed
arrow

NUCARE API LLC

Country
arrow
ASC 2024
Not Confirmed

TIRZEPATIDE

NDC Package Code : 84196-101

Start Marketing Date : 2024-04-15

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNeuland Laboratories- A dedicated 100% API provider.

Flag India
Digital Content Digital Content

Tirzepatide

About the Company : Established in 1984, Neuland Laboratories Limited is a publicly listed company headquartered in Hyderabad, India. The company provides solutions across the entire spectrum of the p...

Established in 1984, Neuland Laboratories Limited is a publicly listed company headquartered in Hyderabad, India. The company provides solutions across the entire spectrum of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. Neuland’s expertise is in the manufacturing of APIs and advanced intermediates from its USFDA-approved facilities. Its core competency lies in the application of powerful process chemistry to manufacturing in a regulatory-compliant environment.
Neuland

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Flag U.S.A
Digital Content Digital Content

Tirzepatide

About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...

Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quality ingredients manufactured in China. Headquartered in the Hauppauge, New York, Rochem has 16 offices spread across the globe to cater to the needs of its customers. Rochem’s operations are fully cGMP compliant and has been audited by the USFDA as well as several multinational organizations. It also trains and audits its partners to ensure all of their technologies and systems are FDA-compliant.
Rochem

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChongqing Sintaho Pharma: A trusted partner globally for chemosynthetic APIs.

Flag China
Digital Content Digital Content

Tirzepatide

About the Company : Sintaho Pharmaceutical Co., Ltd., located in Chongqing, China, contributes to being the most dependable partner for global pharmaceutical companies. Sintaho specializes in chemosyn...

Sintaho Pharmaceutical Co., Ltd., located in Chongqing, China, contributes to being the most dependable partner for global pharmaceutical companies. Sintaho specializes in chemosynthetic APIs (application contains oncology, nervous system, and metabolic diseases and etc.,) with a product portfolio ranging from small molecule APIs, ADC compounds (linkers and payloads) to polypeptides, also provides CDMO services of cytotoxic and OEB4/5 grade APIs.
Chongqing Sintaho Pharmaceutical

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content

Tirzepatide

About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...

Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout the entire API life cycle, from product development through sales. Transo-Pharm serves as a sourcing and regulatory marketing agent for API manufacturers. It aids clients in establishing DMFs and provides GMP consulting. With a dedicated regulatory department, a warehouse, proprietary IPs for API processes, and partnerships with laboratories, Transo-Pharm offers a wide range of services. It operates from its offices in Shanghai, Hong Kong, Singapore, and the US.
Transo Pharm USA Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTranso-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Flag Germany
Digital Content Digital Content

Tirzepatide

About the Company : Founded in 1987, Transo-Pharm is a fully licensed and certified global distributor of pharmaceutical components for the health and veterinary industries. The company supports its c...

Founded in 1987, Transo-Pharm is a fully licensed and certified global distributor of pharmaceutical components for the health and veterinary industries. The company supports its customers throughout the complete lifecycle of APIs, from product development to market research, sourcing, import-export and sales. Transo-Pharm offers a diverse range of products. It qualifies manufacturers for full compliance and serves both as a valuable sourcing agent for its clients and a regulatory marketing agent for API manufacturers. It has offices in Shanghai, Hong Kong, Singapore, the United States, and an affiliated office in Mumbai.
Transo Pharm Handels GmbH

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothUSV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.

Flag India
Digital Content Digital Content

Tirzepatide

About the Company : USV is a leading health care company with focus on Active Pharmaceutical Ingredients (marketed globally with emphasis on regulated markets of USA, European Union and Japan), Brande...

USV is a leading health care company with focus on Active Pharmaceutical Ingredients (marketed globally with emphasis on regulated markets of USA, European Union and Japan), Branded Generics and Bio-therapeutics. USV also specializes in Research and Development in Biotechnology, Drug Delivery and Chemistry.31 APIs are currently on offer, 13 are in advanced stages of development and 14 are under development. Segments covered include Diabetes, Cardiology, CNS, Oncology, Dermatology and Ophthalmology.
USV Private Limited

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content

Tirzepatide

About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...

Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines.
Omgene Company Banner

08

Apino Pharma

China
ASC 2024
Not Confirmed
arrow

Apino Pharma

China
arrow
ASC 2024
Not Confirmed

Tirzepatide

About the Company : Apino Pharma prides itself on being an innovation-driven company that strives to continuously improve its products and services. Our dedicated innovation team collaborates with the...

Apino Pharma prides itself on being an innovation-driven company that strives to continuously improve its products and services. Our dedicated innovation team collaborates with the world’s leading research institutes and universities to develop cutting-edge formulations and technologies that bring value to our customers. We are committed to exploring new opportunities presented by technology, science and global best practices to provide quality products and services that meet and exceed our customers’ needs.
blank

09

ASC 2024
Not Confirmed
arrow
arrow
ASC 2024
Not Confirmed

Tirzepatide

About the Company : Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients a...

Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients and their intermediates, electronic chemical materials and intermediates, large-scale production, sales and services, and provide customized synthetic services according to customer requirements. Sjar-Tech locates in Beijing Economic and Technological Development Zone, has its own R&D and development laboratory. Sjar-Tech has set up a R&D team with rich experience and strong technical strength, most of the practitioners have more than ten years' experience.
blank

10

ASC 2024
Not Confirmed
arrow
arrow
ASC 2024
Not Confirmed

Tirzepatide

About the Company : Hybio is a hi-tech enterprise specializing in the R&D and manufacturing of diverse peptide products. Founded in 1998, after decades of effort, we have grown to be one of the larges...

Hybio is a hi-tech enterprise specializing in the R&D and manufacturing of diverse peptide products. Founded in 1998, after decades of effort, we have grown to be one of the largest and most professional peptide pharmaceutical companies in China. We were one of the first to enter the peptide pharmaceutical industry in China, and we are the only one that has a full range of peptide products and services, including peptide finished dosage products, peptide API products, and peptide CRO&CMO services.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.


Lead Product(s): Bremelanotide Acetate,Tirzepatide

Therapeutic Area: Nutrition and Weight Loss Brand Name: Vyleesi

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 22, 2024

blank

01

ASC 2024
Not Confirmed
ASC 2024
Not Confirmed

Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.

Brand Name : Vyleesi

Molecule Type : Peptide

Upfront Cash : Not Applicable

August 22, 2024

blank

Details:

Zepbound (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently being studied for adults with heart failure with preserved ejection fraction and obesity.


Lead Product(s): Tirzepatide

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Zepbound

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 01, 2024

blank

02

Eli Lilly

U.S.A
arrow
ASC 2024
Not Confirmed

Eli Lilly

U.S.A
arrow
ASC 2024
Not Confirmed

Details : Zepbound (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently being studied for adults with heart failure with preserved ejection fraction and obesity.

Brand Name : Zepbound

Molecule Type : Peptide

Upfront Cash : Not Applicable

August 01, 2024

blank

Details:

BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity.


Lead Product(s): Azelaprag,Tirzepatide

Therapeutic Area: Nutrition and Weight Loss Brand Name: BGE-105

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 29, 2024

blank

03

BioAge Labs

U.S.A
arrow
ASC 2024
Not Confirmed

BioAge Labs

U.S.A
arrow
ASC 2024
Not Confirmed

Details : BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity.

Brand Name : BGE-105

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 29, 2024

blank

Details:

Zepbound (tirzepatide) injection is a first obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.


Lead Product(s): Tirzepatide

Therapeutic Area: Nutrition and Weight Loss Brand Name: Zepbound

Study Phase: ApprovedProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 19, 2024

blank

04

Eli Lilly

U.S.A
arrow
ASC 2024
Not Confirmed

Eli Lilly

U.S.A
arrow
ASC 2024
Not Confirmed

Details : Zepbound (tirzepatide) injection is a first obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Brand Name : Zepbound

Molecule Type : Peptide

Upfront Cash : Not Applicable

July 19, 2024

blank

Details:

Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.


Lead Product(s): Bremelanotide Acetate,Tirzepatide

Therapeutic Area: Nutrition and Weight Loss Brand Name: Vyleesi

Study Phase: Phase IIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 12, 2024

blank

05

ASC 2024
Not Confirmed
ASC 2024
Not Confirmed

Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.

Brand Name : Vyleesi

Molecule Type : Peptide

Upfront Cash : Not Applicable

June 12, 2024

blank

Details:

PT-141 (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.


Lead Product(s): Bremelanotide Acetate,Tirzepatide

Therapeutic Area: Nutrition and Weight Loss Brand Name: PT-141

Study Phase: Phase IProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 02, 2024

blank

06

ASC 2024
Not Confirmed
ASC 2024
Not Confirmed

Details : PT-141 (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.

Brand Name : PT-141

Molecule Type : Peptide

Upfront Cash : Not Applicable

May 02, 2024

blank

Details:

Zepbound (tirzepatide) injection acts by activating both, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 hormone receptors. It is being evaluated for obstructive sleep apnea & obesity.


Lead Product(s): Tirzepatide

Therapeutic Area: Sleep Brand Name: Zepbound

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 17, 2024

blank

07

Eli Lilly

U.S.A
arrow
ASC 2024
Not Confirmed

Eli Lilly

U.S.A
arrow
ASC 2024
Not Confirmed

Details : Zepbound (tirzepatide) injection acts by activating both, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 hormone receptors. It is being evaluated for obstructive sleep apnea & obesity.

Brand Name : Zepbound

Molecule Type : Peptide

Upfront Cash : Not Applicable

April 17, 2024

blank

Details:

The funding will be used to support Phase II clinical development of BioAge’s lead compound BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity.


Lead Product(s): Azelaprag,Tirzepatide

Therapeutic Area: Nutrition and Weight Loss Brand Name: BGE-105

Study Phase: PreclinicalProduct Type: Small molecule

Sponsor: Sofinnova Investments

Deal Size: $170.0 million Upfront Cash: Undisclosed

Deal Type: Series D Financing February 13, 2024

blank

08

BioAge Labs

U.S.A
arrow
ASC 2024
Not Confirmed

BioAge Labs

U.S.A
arrow
ASC 2024
Not Confirmed

Details : The funding will be used to support Phase II clinical development of BioAge’s lead compound BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity.

Brand Name : BGE-105

Molecule Type : Small molecule

Upfront Cash : Undisclosed

February 13, 2024

blank

Details:

Zepbound™ (tirzepatide) injection is the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.


Lead Product(s): Tirzepatide

Therapeutic Area: Nutrition and Weight Loss Brand Name: Zepbound

Study Phase: ApprovedProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 08, 2023

blank

09

Eli Lilly

U.S.A
arrow
ASC 2024
Not Confirmed

Eli Lilly

U.S.A
arrow
ASC 2024
Not Confirmed

Details : Zepbound™ (tirzepatide) injection is the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Brand Name : Zepbound

Molecule Type : Peptide

Upfront Cash : Not Applicable

November 08, 2023

blank

Details:

As part of the collaboration, Lilly will supply tirzepatide and Chorus will provide clinical trial design and execution expertise. BioAge retains worldwide exclusive rights to develop and commercialize BGE-105 (azelaprag) for all indications.


Lead Product(s): Azelaprag,Tirzepatide

Therapeutic Area: Nutrition and Weight Loss Brand Name: BGE-105

Study Phase: PreclinicalProduct Type: Small molecule

Sponsor: Eli Lilly

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration October 26, 2023

blank

10

BioAge Labs

U.S.A
arrow
ASC 2024
Not Confirmed

BioAge Labs

U.S.A
arrow
ASC 2024
Not Confirmed

Details : As part of the collaboration, Lilly will supply tirzepatide and Chorus will provide clinical trial design and execution expertise. BioAge retains worldwide exclusive rights to develop and commercialize BGE-105 (azelaprag) for all indications.

Brand Name : BGE-105

Molecule Type : Small molecule

Upfront Cash : Undisclosed

October 26, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

read-more
read-more

01

Discovery on Target
Not Confirmed
arrow
arrow
Discovery on Target
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO

Dosage Form : SOLUTION

Dosage Strength : 2.5MG/0.5ML

Packaging :

Approval Date :

Application Number : 2541041

Regulatory Info : Prescription

Registration Country : Canada

blank

02

Discovery on Target
Not Confirmed
arrow
arrow
Discovery on Target
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO

Dosage Form : SOLUTION

Dosage Strength : 5MG/0.5ML

Packaging :

Approval Date :

Application Number : 2541068

Regulatory Info : Prescription

Registration Country : Canada

blank

03

Discovery on Target
Not Confirmed
arrow
arrow
Discovery on Target
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO

Dosage Form : SOLUTION

Dosage Strength : 7.5MG/0.5ML

Packaging :

Approval Date :

Application Number : 2541076

Regulatory Info : Prescription

Registration Country : Canada

blank

04

Discovery on Target
Not Confirmed
arrow
arrow
Discovery on Target
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO

Dosage Form : SOLUTION

Dosage Strength : 10MG/0.5ML

Packaging :

Approval Date :

Application Number : 2541084

Regulatory Info : Prescription

Registration Country : Canada

blank

05

Discovery on Target
Not Confirmed
arrow
arrow
Discovery on Target
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO

Dosage Form : SOLUTION

Dosage Strength : 12.5MG/0.5ML

Packaging :

Approval Date :

Application Number : 2541092

Regulatory Info : Prescription

Registration Country : Canada

blank

06

Discovery on Target
Not Confirmed
arrow
arrow
Discovery on Target
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO

Dosage Form : SOLUTION

Dosage Strength : 15MG/0.5ML

Packaging :

Approval Date :

Application Number : 2541106

Regulatory Info : Prescription

Registration Country : Canada

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty